<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="74035">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02126943</url>
  </required_header>
  <id_info>
    <org_study_id>AC-055-503</org_study_id>
    <nct_id>NCT02126943</nct_id>
  </id_info>
  <brief_title>OPsumit USers Registry</brief_title>
  <acronym>OPUS</acronym>
  <official_title>US-based, Observational, Drug Registry of Opsumit® (Macitentan) New Users in Clinical Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational drug registry developed to characterize the safety profile
      (including primarily potential serious hepatic risks) and to describe clinical
      characteristics and outcomes of patients newly treated with Opsumit in the post-marketing
      setting.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>To estimate incidence rates for specified outcomes.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Liver test abnormalities/ Occurrence of Hepatic Adverse Events (HAEs)/ Occurrence of any other AEs/ Discontinuation of Opsumit and reason for stopping therapy/ Hospitalization and death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To describe demographic and clinical characteristics of patients treated with Opsumit at enrollment and during observation period.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>To describe PAH treatment patterns at enrollment and during observation period.</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Pulmonary Arterial Hypertension</condition>
  <condition>PAH</condition>
  <arm_group>
    <arm_group_label>Opsumit (macitentan)</arm_group_label>
    <description>10 mg tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Opsumit (macitentan)</intervention_name>
    <description>10 mg tablets</description>
    <arm_group_label>Opsumit (macitentan)</arm_group_label>
    <other_name>ACT-064992</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients newly treated with Opsumit
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients newly treated with Opsumit defined as a new user of therapy, initiated ≤ 30 days
        prior to enrollment visit.

        Signed ICF

        Exclusion Criteria:

        Previous user of Opsumit defined as patient who initiated therapy &gt;30 days prior to
        enrollment.

        Patients enrolled in any ongoing clinical trials
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>V McLaughlin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Chair of the OPUS scientific committee (OSC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Rosenberg</last_name>
    <email>medinfo@actelion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Global Medical Information</last_name>
      <email>medinfo@actelion.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>April 29, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pulmonary arterial hypertension</keyword>
  <keyword>PAH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
